<DOC>
	<DOCNO>NCT01992042</DOCNO>
	<brief_summary>This research study provide novel opportunity examine intra-prostatic tumour inhibitory effect statins men prostate cancer undergo surgery .</brief_summary>
	<brief_title>Novel Window Opportunity Trial Evaluate Impact Statins Oppose Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<criteria>The study population consist patient localized prostate cancer elect radical prostatectomy primary treatment . Eligible patient prostate cancer Gleason Score ≥ 7 . Patients meet follow inclusion criterion eligible participate study : 1 . Men &gt; 18 &lt; 75 year age 2 . Willing able provide inform consent , either alone aid translator 3 . Histologically confirm prostate cancer determine transrectal ultrasound ( TRUS ) guide prostate biopsy perform within 6 month study enrolment 4 . Prostate cancer Gleason grade ≥ 7 involve least 30 % one unfragmented biopsy core 5 . Candidates radical prostatectomy consider surgically resectable , either open robotic , urologic evaluation 6 . Normal organ marrow function define follow criterion : i. absolute neutrophil count &gt; 1,500/uL ii . platelet &gt; 100,000/uL iii . total bilirubin &lt; 1.5 X institutional ULN iv . AST ( SGOT ) ALT ( SGPT ) &lt; 1.5 X institutional ULN v. creatinine &lt; 1.5 X institutional ULN 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Exclusion Criteria Any patient meeting one follow exclusion criterion may enter study : 1 . Previous current use neoadjuvant hormonal management prostate cancer ( surgical castration hormonal manipulation , include GnRH receptor agonist , GnRH receptor antagonist , antiandrogens , estrogen , megestrol acetate ketoconazole ) 2 . History receive radiation pelvic area 3 . Past current use 5alpha reductase inhibitor finasteride and/or dutasteride 4 . History bilateral orchiectomy , adrenalectomy , hypophysectomy 5 . Statin use within 2 year prostate cancer diagnosis 6 . Known hypersensitivity towards component investigational medicinal product . 7 . Previous history presence another malignancy , prostate cancer treat squamous / basal cell carcinoma skin , within last five year 8 . Clinically significant laboratory abnormality ( e.g . severe renal hepatic impairment ) judgment Investigator would affect patient 's health outcome trial 9 . Clinically significant disorder ( prostate cancer ) include , limited , renal , haematological , gastrointestinal , endocrine , cardiac , neurological , psychiatric disease , alcohol drug abuse condition , may affect patient 's health outcome trial judge Investigator 10 . Use natural medicine think endocrine effect prostate cancer ( e.g . saw palmetto St. John 's Wort ) 4 week prior enrollment . 11 . Use drug list Prohibited Medications List 12 . Mental incapacity language barrier preclude adequate understanding co operation 13 . Use investigational drug within last 28 day precede Screening Visit longer consider possibly influence outcome current trial 14 . Patients unable unwilling undergo MRI testing</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>